Lee's Pharmaceutical Holdings Limited risk profile
38 Normal where most of the sector sits
Measured 10 September 2026 from 0950.HK's filed statements. Recomputed nightly.
38 (Normal), driven by Market expectation at 81, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 81 | Acute | Volatile | One-year price volatility — 56.3% |
| Operating pressure | 42 | Elevated | Worsening | Costs outgrowing revenue — +0.3 percentage points |
| Cash conversion | 31 | Normal | Easing | Capital spending against operating cash — 0.70x |
| Leverage and coverage | 15 | Contained | Stable | Current ratio — 1.03x |
| Competitive position | 38 | Normal | Stable | R&D-intensity gap against peers — -44.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 34Johnson & Johnson 39Abbvie Inc 58Roche Holding AG 36Merck & Co Inc 35Unitedhealth Group Inc 49Novartis AG 30Astrazeneca plc 33Thermo Fisher Scientific Inc 47AMGEN Inc 47Novo Nordisk A/S 23Abbott Laboratories 37
Financials, valuation and price history for Lee's Pharmaceutical Holdings Limited